阿哌沙班与华法林治疗重度肥胖患者静脉血栓栓塞的多中心回顾性研究
该多中心回顾性研究纳入1099例BMI≥40 kg/m2或体重≥120 kg的静脉血栓栓塞患者,比较阿哌沙班与华法林的疗效与安全性。结果显示阿哌沙班组复发VTE风险显著低于华法林组(HR=0.54,95%CI:0.29-0.97,P=0.04),大出血、临床相关非大出血及全因死亡率无显著差异。
要点
- 重度肥胖患者使用阿哌沙班治疗VTE,复发风险低于华法林。
- 阿哌沙班与大出血、临床相关非大出血及全因死亡风险无显著差异。
- 研究支持阿哌沙班在BMI≥40 kg/m2或体重≥120 kg患者中有效且安全。
核心结论
- 在BMI≥40 kg/m2或体重≥120 kg的患者中,阿哌沙班治疗VTE有效且安全。
研究设计与样本
- 多中心回顾性研究,比较阿哌沙班与华法林治疗VTE,纳入2012年1月1日至2019年12月31日期间BMI≥40 kg/m2或体重≥120 kg的患者,共1099例(阿哌沙班314例,华法林785例)。
主要发现
- 阿哌沙班组复发VTE时间显著长于华法林组(P=0.018)。
- 控制混杂因素后,阿哌沙班与华法林相比复发VTE风险降低(HR=0.54,95%CI:0.29-0.97,P=0.04)。
- 两组间大出血、临床相关非大出血及全因死亡率无显著差异。
临床怎么用
- 对于BMI≥40 kg/m2或体重≥120 kg的VTE患者,可考虑使用阿哌沙班作为抗凝治疗选择。
局限性
- 回顾性研究设计可能存在混杂和选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Direct oral anticoagulants are the standard of care for venous thromboembolism (VTE) treatment. These agents are recommended regardless of patient weight and body mass index (BMI). However, there remains limited evidence supporting the use of apixaban in patients with severe obesity with a BMI ≥40 kg/m2 or weight ≥120 kg. The purpose of this study was to evaluate the efficacy and safety of apixaban for VTE in patients with a BMI ≥40 kg/m2 or weight ≥120 kg. DESIGN: This multi-center, retrospective study compared the use of apixaban versus warfarin in patients with severe obesity for the treatment of VTE between January 1, 2012, and December 31, 2019. Patients were identified by diagnosis codes for acute VTE and a weight ≥120 kg or BMI ≥40 kg/m2 . The primary efficacy outcome was time to recurrence of VTE within 12 months, and the primary safety outcome was time to major bleeding within 12 months. Secondary outcomes included incidence of recurrent VTE, major bleeding, clinically relevant non-major bleeding (CRNMB), all-cause mortality, number of total hospital encounters, and switch in anticoagulant. MAIN RESULTS: A total of 1099 patients were included in the study. Of these, 314 patients received apixaban and 785 received warfarin. The mean weight and BMI were 137 kg and 46 kg/m2 , respectively. Time to recurrent VTE was significantly longer in those treated with apixaban compared to warfarin (p = 0.018). After controlling for confounding factors, apixaban use was associated with a reduced risk of recurrent VTE compared to warfarin (hazard ratio [HR] = 0.54, 95% confidence interval [CI]: 0.29-0.97, p = 0.04). There were no significant differences in major bleeding, CRNMB, or all-cause mortality between groups. CONCLUSION: In patients with a BMI ≥40 kg/m2 or weight ≥120 kg, apixaban appears to be effective and safe for the treatment of VTE.
引用
- Crouch A, Ng TH, Kelley D, et al. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy. 2021. PMID: 34904263. doi:10.1002/phar.2655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。